- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe atopic dermatitis Uncontrolled severe asthma
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Dupilumab – March 2025
Dupilumab; Injection 200 mg in 1.14 mL single dose pre-filled pen, Injection 300 mg in 2 mL single dose prefilled pen; Dupixent®
Last updated
12 March 2025